NEW YORK, NY / ACCESSWIRE March 16, 2017 / TriPoint Global Equities, LLC (“TriPoint”), a FINRA member and leading boutique investment bank that provides companies with capital raising and corporate and strategic advisory services, today announced that its online electronic platform, BANQ® (www.BANQ.co), has launched its Regulation A+ initial public offering for Myomo, Inc. (www.banq.co/listings/myomo).
Myomo is a leading manufacturer of myoelectric orthotics that provides expanded mobility for those suffering from neurological disorders and upper-limb paralysis. Myomo serves patients who have partial paralysis or a weakened arm through its patented medical robotics technology that can restore a patient’s ability to use their arms and hands again so that they can return to work, live independently, and reduce their cost of care.
Myomo is seeking to become the first company to launch a Regulation A+ IPO with listing on the New York Stock Exchange MKT (NYSE MKT). TriPoint Global Equities, LLC, working with its online division BANQ® (www.banq.co), will act as the lead managing selling agent and bookrunner for the offering. Myomo intends to use the proceeds from the offering to fund sales and marketing, product development, repayment of debt, and for working capital and other general corporate purposes.
“TriPoint has been working hard for the past several years to educate the market on the benefits of Regulation A and how we intend to use it to bring back the Small Cap IPO,” said Mark Elenowitz, CEO of TriPoint. “Myomo will hopefully be first of many TriPoint issuers that trade on higher exchanges and allows the crowd to participate in opportunities that, in the past, have been reserved for the Wall Street elite.”
Myomo Allows Patients to Regain Essential Mobility
Myomo’s core technology was originally developed at the Massachusetts Institute of Technology (MIT) in collaboration with medical experts affiliated with Harvard Medical School. In 2006, the company was spun out from MIT and became the exclusive licensee of two patents owned by MIT that are behind the myoelectric technology. Since then, Myomo has launched three generations of its technology and expanded its patent portfolio. The latest generation MyoPro® custom-fabricated orthosis is specified for each patient and easily donned by the patient to perform everyday functional tasks at home or at work.
The MyoPro is a myoelectric arm orthosis designed to support a weak arm. It can enable individuals to self-initiate and control movements of a partially paralyzed or weakened arm and hand using their own muscle signals. When the user tries to bend their arm, sensors in the MyoPro brace detect the weak muscle signal, which activates the motor to move the arm in the desired direction. The user is completely controlling their own arm and hand; the brace amplifies their weak muscle signal to help bend and move their arm. With the orthosis, a paralyzed individual, such as one who has suffered a brachial plexus injury, stroke, or other neuromuscular disorder, can perform activities of daily living, including feeding themselves, carrying objects, and doing household tasks.
Due to the large number of strokes, spinal cord injuries, and other neurological conditions which occur each year, the potential market opportunity worldwide may consist of millions of individuals and is growing each year.
The Opportunity to Invest in Myomo
Myomo has previously raised more than $20 million from management, individual investors with healthcare and high-technology experience, as well as Mountain Group Capital. The company seeks to raise up to $15 million in its IPO under Regulation A+ and then, in succession and subject to NYSE requirements, be listed on the NYSE MKT as “MYO.” Individuals interested in learning more about the Myomo Regulation A+ investment opportunity can visit http://www.banq.co/listings/myomo.
About Myomo, Inc.
Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT, Harvard Medical School, and by the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury, such as brachial plexus injury, or other neuromuscular disability, such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently, and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.
About BANQ & TriPoint
TriPoint Global Equities, LLC (“TriPoint”), a FINRA member firm, is a boutique investment bank, with corporate finance and sales and trading services. TriPoint focuses on providing U.S. and non-U.S. companies of up to $500 million in revenue with capital raising, corporate finance advisory services, and assistance with navigating the regulatory environment for companies listing on U.S. markets. TriPoint Global maintains specialized practices in institutional private placements, sales and trading, mergers and acquisitions, and corporate finance. BANQ®, the online division of TriPoint, www.banq.co, is an electronic investment banking platform that streamlines the matching of investors with quality growth companies and alternative investment opportunities. BANQ® provides investors access to exciting companies with exposure to rapidly growing sectors and new technologies. BANQ® takes the entire public and private offering process digital and online, providing access to U.S. opportunities and offerings in the U.S. markets. BANQ® widely markets its offerings utilizing the new general solicitation and advertising rules promulgated by the U.S. Securities & Exchange Commission, in response to the passage of the JOBS Act of 2012 including Reg A+ and Reg D. TriPoint has offices in New York City, Jericho, NY, Akron, OH, Beijing, China, and Washington, D.C. For more information, please visit http://www.tripointglobalequities.com.
SEC Disclaimer
An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that Myomo may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits, or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement here: https://www.sec.gov/cgi-bin/browse-edgar?company=myomo+inc&owner=exclude&action=getcompany. You should read the offering circular before making any investment.
Forward-Looking Statements
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as “expected,” “anticipated,” “projected,” and “forecasted.” Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.
To Inquire for BANQ Services:
inquiries@banq.co
www.banq.co
SOURCE: TriPoint Global Equities, LLC
ReleaseID: 457469
